2016 expected to be good year for real estate in Tri-Counties
Despite the slight increase of interest rates and the drought’s persistence, real estate brokers are bullish on 2016. The Federal Reserve’s decision to gradually raise interest rates throughout 2016 will not likely have a short-term impact on development and real estate activity, industry sources told the Business Times. And while the city of Pismo Beach Read More →
Thousand Oaks’ Sports Academy aims to develop student athletes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Developers respond to aging workforce with senior housing
The Tri-Counties are preparing for the silver tsunami. The oncoming wave is the surge of the country’s aging workforce. Nearly one-fifth of the U.S. population will be 65 or older come 2030, according to the U.S. Census. There are dozens of housing developments in the pipeline throughout the Tri-Counties that aim to accommodate the rapidly Read More →
Amgen increases dividend to $1 per share
Amgen increased its yearly dividend 27 percent this year to $1 per share. Previously, the dividend had been 79 cents per share for the Thousand Oaks-based biotech giant. Shares jumped after news of the 27-cent dividend broke. The announcement was made just after the markets closed at 1:11 p.m. Amgen closed the trading day up Read More →
Ceres plans to raise $6.7 million through public stock offering Dec. 17
Ceres, a Thousand Oaks-based agriculture-biotechnology company, priced shares at 40 cents each on Dec. 15 for its follow-on public offering on Dec. 17. Ceres plans to raise $6.7 million through the offering, which will be comprised of 600,000 shares of common stock, 6,460 shares of preferred stock convertible into 16,150,000 shares of common stock, and Read More →
Amgen reacquires rights to sell 3 drugs worldwide
Amgen reacquired all rights to sell three drugs worldwide on Dec. 14. The Thousand Oaks-based biotech giant said it reacquired the rights to Prolia, Vectibix and Xgeva in 48 ccountries from British pharmaceutical company GlaxoSmithKline. The agreement includes large countries like Australia, China and Brazil. Prolia is designed to raise bone density in people with Read More →
Thousand Oaks Boulevard improvements working
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
